Craig Roder

For Corporates
Analyzing Healthcare M&A Trends: Q1 2024 Insights
Healthcare M&A activity remained robust in the first quarter of 2024, with 29 transactions vs. 28 in 2023. Biopharma was the most active healthcare subsector, representing 45% of deal volume, while Services activity remained dampened despite notable transactions such as Novo Holdings’ acquisition of Catalent. We expect Biopharma M&A activity to remain robust as large pharmaceutical companies attempt to fill revenue and pipeline gaps via acquisitions of late- or commercial-stage companies. We expect pre-commercial biopharma companies to continue pursue strategic alternatives, including mergers, private company mergers and cash-out transactions as a result of the dynamic capital markets environment.
LEARN MORE
For Investors
Sectors
Insights
About
- Firm
- Careers
- News
- Contact
- Transactions

Team
Related Team
Craig Roder

Craig Roder is a Managing Director of Institutional Equities at Leerink Partners.

Mr. Roder brings over two decades of experience and expertise in institutional equity sales to Leerink Partners. Prior to joining the Firm in 2023, Mr. Roder served as Managing Director at Oppenheimer & Co. Inc.. During his tenure at Oppenheimer, Mr. Roder led the firm’s western regional Institutional Sales effort in addition to covering some of the largest Hedge Funds/Long only clients of the firm. Prior to Oppenheimer, Mr. Roder was a Vice President of Investments at UBS.

Mr. Roder earned his B.A. from the University of California, Berkeley.

Partner With Us

Contact Us